Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.45 |
| ▸ | GRK2 | P25098 | 4/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26107873 | 0.87 | HDAC3 (0.65) | HDAC3HDAC6NCOR2AOC3 | |
| SCHEMBL1436121 | 0.81 | NR1H2 (0.61) | HDAC3HDAC6NCOR2L3MBTL1HPGDS | |
| SCHEMBL1039187 | 0.81 | NR1H2 (0.59) | HDAC3HDAC6NCOR2KDM4EAOC3 | |
| SCHEMBL15299350 | 0.78 | HDAC3 (0.60) | HDAC3HDAC6NCOR2AOC3 | |
| SCHEMBL1040640 | 0.78 | HDAC3 (0.56) | HDAC3HDAC6NCOR2KDM4EAOC3 | |
| SCHEMBL4859334 | 0.78 | NR1H2 (0.56) | HDAC3HDAC6NCOR2AOC3 | |
| SCHEMBL1041002 | 0.77 | HDAC3 (0.55) | HDAC3HDAC6NCOR2KDM4EAOC3 | |
| SCHEMBL1435798 | 0.77 | SMN1; SMN2 (0.63) | JAK2KDM4EMAPK8MAPK9 | |
| SCHEMBL11589319 | 0.77 | NR1H2 (0.67) | JAK2KDM4EL3MBTL1HPGDS | |
| SCHEMBL2769054 | 0.75 | JAK2 (0.49) | JAK2KDM4EL3MBTL1ROCK2GRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | HDAC3 1779/4885HDAC6 534/4885NCOR2 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.